Guidance for Moving to Advanced Systemic Therapy and Biologic Agents

Author(s):

Linda Stein Gold, MD,Alexandra K. Golant, MD

Panelists discuss recent guideline changes regarding advanced systemic therapy in atopic dermatitis (AD), focusing on when to transition a patient to systemic agents and when biologics should be considered for the treatment of moderate to severe AD.

EP: 1.Heterogenous Presentation Of Atopic Dermatitis

EP: 2.Use of Biopsy and Diagnosing New-Onset AD

EP: 3.Treatment Options in Atopic Dermatitis

EP: 4.Improvement in Standard of Care in Atopic Dermatitis

EP: 5.Improvement in Patients’ Qualify of Life with Atopic Dermatitis Treatments

Now Viewing

EP: 6.Guidance for Moving to Advanced Systemic Therapy and Biologic Agents

EP: 7.IL-13–Targeting Agents in Atopic dermatitis

EP: 8.Efficacy Data With IL-13 Targeting Agents in Atopic Dermatitis

EP: 9.Less Frequent Administration of Lebrikizumab for Atopic Dermatitis

EP: 10.Switching or Staying Within the Treatment Class

EP: 11.Use of Combination Therapy in Atopic Dermatitis

EP: 12.Safety Data With Biologics in Atopic Dermatitis

EP: 13.Data With IL-13– Targeting Agents in Atopic Dermatitis in Clinical Practice

EP: 14.Lebrikizumab in Patients With Skin of Color (ADmirable)

Video content above is prompted by the following:

Discuss changes in patients’ quality of life with atopic dermatitis treatments.
Recent changes in guidelines and moving to advanced systemic therapy in AD.
When would you transition a patient to systemic agents? When should biologics be considered for treatment of moderate to severe AD?